Reva Medical (ASX:RVA) said today that it inked a deal with Bio Vascular Group to distribute Reva’s Fantom bioresorbable scaffold in Italy.
The partnership expands Reva’s commercial activities to Italy, adding to its ongoing efforts in Germany, Switzerland, Austria and Turkey.
The San Diego, Calif.-based company also touted today that the first commercial implant of its Fantom scaffold in Italy was conducted by Dr. Bernardo Cortese of Clinica San Carlo – Casa di Cura Polispecialistica.
“In Italy, we stay on the leading edge of technology to offer the best possible care to our patients,” Cortese said in prepared remarks. “During the implant procedure, I was able to see the technical advantages of Fantom over first-generation bioresorbable scaffolds such as x-ray visibility and ease-of-use. Second-generation, thin strut bioresorbable scaffolds like Fantom have the potential to improve outcomes, and we are excited to have this treatment option available for Italian patients.”
“With this partnership, we are delivering on our ongoing commitment to expand geographic access to Fantom,” Reva CEO Reggie Groves added. “Bio Vascular offers country-wide distribution coverage in Italy. The company’s proven track record with interventional cardiology devices, demonstrated relationships with physicians and commitment to patient care make it an ideal partner for us.”
Last month, Reva nabbed CE Mark clearance for its entire line of Fantom Encore bioresorbable, drug-eluting scaffolds. The approval covered Reva’s Fantom 3.0 and 3.5 mm diameter devices, helping the company expand beyond its already-approved 2.5 mm diameter scaffold.
